Sport Investors League
  • Politics
  • Stocks
  • Investing
  • Business

Sport Investors League

  • Politics
  • Stocks
  • Investing
  • Business
Business

Pfizer CEO says tariff uncertainty is deterring further U.S. investment in manufacturing, R&D

by admin April 30, 2025
April 30, 2025
Pfizer CEO says tariff uncertainty is deterring further U.S. investment in manufacturing, R&D

Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump’s planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and research and development. 

Bourla’s remarks on the company’s first-quarter earnings call came in response to a question about what Pfizer wants to see from tariff negotiations that would push the company to increase investments in the U.S. It comes as drugmakers brace for Trump’s levies on pharmaceuticals imported into the country — his administration’s bid to boost domestic manufacturing.

“If I know that there will not be tariffs … then there are tremendous investments that can happen in this country, both in R&D and manufacturing,” Bourla said on the call, adding that the company is also hoping for “certainty.”

“In periods of uncertainty, everybody is controlling their cost as we are doing, and then is very frugal with their investment, as we are doing, so that we are prepared for remit. So that’s what I want to see,” Bourla said.

Bourla noted the tax environment, which had previously pushed manufacturing abroad, has “significantly changed now” with the establishment of a global minimum tax of around 15%. He said that shift hasn’t necessarily made the U.S. more attractive, saying “it’s not as good” to invest here without additional incentives or clarity around tariffs.

“Now [Trump] I’m sure — and I know because I talked to him — that he would like to see even a reduction in the current tax regime particularly for locally produced goods,” Bourla said, adding a further decrease would be would be a strong incentive for manufacturing in the U.S.

Unlike other companies grappling with evolving trade policy, Pfizer did not revise its full-year outlook on Tuesday. However, the company noted in its earnings release that the guidance “does not currently include any potential impact related to future tariffs and trade policy changes, which we are unable to predict at this time.”

But on the earnings call on Tuesday, Pfizer executives said the guidance does reflect $150 million in costs from Trump’s existing tariffs.

“Included in our guidance that we didn’t really speak about is there are some tariffs in place today,” Pfizer CFO Dave Denton said on the call.

“We are contemplating that within our guidance range and we continue to again trend to the top end of our guidance range even with those costs to be incurred this year,” he said.

This post appeared first on NBC NEWS

0
FacebookTwitterGoogle +Pinterest
previous post
The Best Five Sectors, #17
next post
Crypto Market Recap: Loopscale Faces US$5.8 Million Hack, Coinbase Preps New Institutional Offering

Related Posts

21 million Miniverse toy sets recalled after reports...

June 27, 2024

Target lowering prices on 5,000 frequently bought items

May 21, 2024

Nissan could face cost-cutting ‘carnage’ in Honda merger,...

December 25, 2024

Walmart employees are now wearing body cameras in...

December 18, 2024

Hasbro says it’s taking steps to offset China...

February 22, 2025

Trump Media shares sink to new post-merger low...

September 13, 2024

How the Inflation Reduction Act sparked a manufacturing...

August 21, 2024

Consumer protection board sues Walmart and fintech firm...

December 25, 2024

About 800,000 BetterHelp online therapy customers receive refund...

May 11, 2024

Tesla investors want Elon Musk to answer questions...

January 31, 2025

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent

    • Trump warns of ‘massive bloodshed’ if Hamas fails to agree to peace deal: ‘MOVE FAST’

      October 6, 2025
    • Self-described ‘unapologetic supporter of Israel’ John Fetterman weighs in as Trump seeks to broker peace deal

      October 6, 2025
    • More lawmakers say they’re rejecting paychecks as government shutdown drags on

      October 6, 2025
    • Boundiali indicated gold resources grows by 53% in two month

      October 6, 2025
    • Platinum Price Pushes Past US$1,600 to Fresh 12 Year High

      October 6, 2025

    Categories

    • Business (1,115)
    • Investing (3,188)
    • Politics (3,890)
    • Stocks (1,155)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sportinvestorsleague.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 sportinvestorsleague.com | All Rights Reserved